Search
Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigational[A232863] Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs.
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.
Calcium
go.drugbank.com/drugs/DB01373ApprovedInvestigationalNutraceuticalCalcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions i...
Mixtures: Doctor's Choice Brand for Men, Vitality Brand Calcium Plus TabPhenol
go.drugbank.com/drugs/DB03255ApprovedInvestigationalPhenol is an antiseptic and disinfectant. It is active against a wide range of micro-organisms including some fungi and viruses, but is only slowly effective against spores. Phenol has been used to disinfect skin and to relieve itching. ...
Mixtures: Vaseline Brand Lip Therapy Medicated TubeDiet
go.drugbank.com/conditions/DBCOND0034841Type 2 Diabetes
go.drugbank.com/conditions/DBCOND0030616Riboflavin
go.drugbank.com/drugs/DB00140ApprovedInvestigationalNutraceuticalVet approvedNutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast. It occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms ...
Mixtures: Daily Energy Brand B-complex, Doctor's Choice Brand for MenSusoctocog alfa
go.drugbank.com/drugs/DB11606ApprovedInvestigationalSusoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection.
Vericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigational[L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure.
Capmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigationalManufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have